

Claims

We Claim:

1. A method of treating or preventing  
intermittent claudication in a subject comprising the  
5 step of administering a therapeutically effective amount  
of GLP-1 molecule.

2. A method of treating or preventing  
skeletal muscle injury caused by ischemia and/or  
reperfusion in a subject comprising the step of  
10 administering a therapeutically effective amount of GLP-1  
molecule.

3. The method according to claim 1 or 2,  
wherein the GLP-1 molecule is selected from the group  
consisting of GLP-1(7-36)NH<sub>2</sub>, GLP-4(7-37), and exendin-4.

4. The method according to claim 1 or 2,  
15 wherein the GLP-1 molecule is selected from the group  
consisting of GLP-1(7-36)NH<sub>2</sub> and GLP-1(9-36)NH<sub>2</sub>.

5. The method according to claim 1 or 2,  
wherein the subject is also administered free radical  
20 scavengers.

6. The method according to claim 5, wherein  
the free radical scavenger is selected from the group  
consisting of glutathione, melatonin, Vitamin E, and  
superoxide dismutase.

7. The method according to claim 1 or 2,  
25 wherein the subject is also administered glucose.

8. The method according to claim 7, wherein  
the subject is also administered potassium.

9. The method according to claim 1 or 2,  
wherein the subject is suffering from PVD.

10. The method according to claim 1 or 2,  
wherein the subject is human.

5 11. The method according to claim 1 or 2,  
wherein the GLP-1 is administered by an infusion pump or  
by subcutaneous injection of a slow release formulation.

10